share_log

NexImmune | 8-K: Current report

NexImmune | 8-K: Current report

NexImmune | 8-K：重大事件
美股sec公告 ·  06/11 16:34
Moomoo AI 已提取核心信息
NexImmune, Inc. has reported significant corporate governance changes in a recent Form 8-K filing with the SEC dated June 7, 2024. The company's Board of Directors approved an amendment to the Amended and Restated Bylaws, which now stipulates that a quorum at stockholder meetings will require one-third of the voting power of all shares entitled to vote. This amendment took effect on the same day. Additionally, on June 11, 2024, NexImmune filed a Certificate of Designation for one share of Series A Preferred Stock, which has special voting rights tied to certain company dissolution-related proposals but is not convertible into common stock and does not entitle the holder to dividends. The preferred share will have a significant number of votes equivalent to the outstanding common shares if a Voting Proposal related to the company's dissolution receives more 'for' votes than 'against' or 'abstain' votes. The preferred share may also be redeemed by the company at any time for $0.01, subject to Delaware law and the Board's fiduciary duties.
NexImmune, Inc. has reported significant corporate governance changes in a recent Form 8-K filing with the SEC dated June 7, 2024. The company's Board of Directors approved an amendment to the Amended and Restated Bylaws, which now stipulates that a quorum at stockholder meetings will require one-third of the voting power of all shares entitled to vote. This amendment took effect on the same day. Additionally, on June 11, 2024, NexImmune filed a Certificate of Designation for one share of Series A Preferred Stock, which has special voting rights tied to certain company dissolution-related proposals but is not convertible into common stock and does not entitle the holder to dividends. The preferred share will have a significant number of votes equivalent to the outstanding common shares if a Voting Proposal related to the company's dissolution receives more 'for' votes than 'against' or 'abstain' votes. The preferred share may also be redeemed by the company at any time for $0.01, subject to Delaware law and the Board's fiduciary duties.
NexImmune，Inc.最近在一份8-K表格中报告了重大的公司治理变化，该表格于2024年6月7日提交给证券交易委员会。公司的董事会批准了对修正后的公司章程的修正案，现规定在股东大会上的法定人数需要占有所有应有投票权的股份的三分之一。该修正案于同一天生效。此外，于2024年6月11日，NexImmune提交了一份指定证书，用于一股A系列优先股，该股票与特定公司解散相关提案的特殊表决权相挂钩，但不能转换为普通股并且不享有红利。如果与公司的解散相关的表决提案获得比反对票或弃权票更多的支持票，则优先股将享有等同于普通股的大量投票权。此外，该优先股也可根据特定条件随时由公司赎回，每股价值$0.01，视特拉华州法律和董事会的受托责任而定。
NexImmune，Inc.最近在一份8-K表格中报告了重大的公司治理变化，该表格于2024年6月7日提交给证券交易委员会。公司的董事会批准了对修正后的公司章程的修正案，现规定在股东大会上的法定人数需要占有所有应有投票权的股份的三分之一。该修正案于同一天生效。此外，于2024年6月11日，NexImmune提交了一份指定证书，用于一股A系列优先股，该股票与特定公司解散相关提案的特殊表决权相挂钩，但不能转换为普通股并且不享有红利。如果与公司的解散相关的表决提案获得比反对票或弃权票更多的支持票，则优先股将享有等同于普通股的大量投票权。此外，该优先股也可根据特定条件随时由公司赎回，每股价值$0.01，视特拉华州法律和董事会的受托责任而定。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息